Unlock instant, AI-driven research and patent intelligence for your innovation.

Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

A technology for cell proliferation and disease, applied in drug combination, drug delivery, urinary system diseases, etc.

Pending Publication Date: 2018-06-08
NYMOX CORP
View PDF58 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These non-selective antagonists have side effects associated with antagonism of α1d and α1b receptors in the peripheral vasculature, such as hypotension and syncope

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
  • Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
  • Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0303] In one study, 97 patients with or without prior conventional oral drug therapy for benign prostatic hyperplasia (BPH) received the amino acid sequence Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys - Double-blind single-dose study of specific peptides of Leu-Glu-Ile-Lys-Arg-Cys-Leu ("drug (DRUG)" described below) (n=61) or vehicle only (placebo) (n=36) injection, and clinical follow-up for 2-5 years. Patients with BPH were administered the following intraprostatic intravenous injections under ultrasound guidance by a urologist in an office setting under double-blind conditions: a) DRUG in phosphate-buffered saline ("PBS") at pH 7.2, or b) PBS only. Patients were followed up for 2 to 5 years, and regular physical examination, laboratory examination and symptom assessment were performed. Receive a) DRUG followed by conventional oral medications for BPH (including alpha blockers such as tamsulosin, terazosin, doxazosin, silodosin, etc. or 5-alpha reductase Inhibitors such as f...

Embodiment 2

[0311] In one study, 30 patients who had not previously taken conventionally approved oral medications for BPH received a double-blind single injection of DRUG (n=21) or vehicle only (placebo) (n=9), followed by clinical trials. Follow up for 2-5 years. Patients from the above drug and vehicle-only placebo groups who had not previously received conventional oral medication and subsequently continued on conventional oral medication were assessed for their response to conventional oral BPH medication. Surprisingly, after routine oral BPH medication, the improvement in BPH symptom response in patients receiving DRUG was significantly better than expected (mean improvement in symptom score of 7.48 points, compared to 3-5 points improvement with conventional oral medication alone, p <.02), while the placebo-only patients did not (average improvement of 2.33 points, compared to the expected improvement of 3-5 points).

[0312] According to the present example, the use of NTP peptid...

Embodiment 3

[0314] In another study, BPH patients were given intravenous injections of PBS pH 7.2 vehicle alone under ultrasound guidance by urologists under double-blind conditions. Patients were followed up for 1 to 3 years, and regular physical examination, laboratory examination and symptom evaluation were performed. Patients receiving PBS vehicle only and patients subsequently also receiving conventional oral medications used to treat BPH (eg, alpha blockers) before and after receiving additional injections of the medication in phosphate-buffered saline pH 7.2 ("PBS") to evaluate. Symptom assessment was measured by the International Prostate Symptom Score (IPSS), a quantitative score used to assess improvement or worsening of prostate symptoms. Differences from baseline IPSS were compared for outcomes after crossover with DRUG in patients using blinded PBS only plus conventional oral medication and the same patients on oral medication. Surprisingly, subjects who took BPH medication...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combinationwith additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intraprostatically, intratumorally, intranasally, topically, transdermallly, etc., either alone or conjugated to a carrier to a mammal in need thereof.

Description

[0001] This application claims priority to US Nonprovisional Patent Application No. 14 / 738,551, filed June 12, 2015, which is incorporated herein by reference in its entirety. Background technique [0002] 1. Fields of Implementation [0003] Such embodiments include the use of compositions comprising small peptide-based compounds in combination with at least one other active agent and a pharmaceutically acceptable carrier for the treatment of conditions requiring removal or destruction of cellular components, such as human benign or malignant tumors. Compositions and methods. Such methods include, but are not limited to, intramuscular, oral, intravenous, intraperitoneal, intracerebral (intraparenchymal), intraventricular, intralesional, intraocular, intraarterial, intrathecal, intratumoral, intranasal, topical, Compositions are administered transdermally, subcutaneously or intradermally. [0004] 2. Description of related technologies [0005] The nature of many medical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K38/10A61P35/00
CPCA61K38/1709A61K31/58A61K45/06A61K31/18A61K31/404A61K31/4985A61K31/517A61K38/10A61P13/08A61P35/00A61P43/00A61K2300/00A61K9/0053
Inventor P·艾弗白克
Owner NYMOX CORP